GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Penumbra Inc (NYSE:PEN) » Definitions » Total Liabilities

PEN (Penumbra) Total Liabilities : $380 Mil (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Penumbra Total Liabilities?

Penumbra's Total Liabilities for the quarter that ended in Mar. 2025 was $380 Mil.

Penumbra's quarterly Total Liabilities increased from Sep. 2024 ($374.84 Mil) to Dec. 2024 ($382.25 Mil) but then declined from Dec. 2024 ($382.25 Mil) to Mar. 2025 ($380.43 Mil).

Penumbra's annual Total Liabilities increased from Dec. 2022 ($372.03 Mil) to Dec. 2023 ($377.36 Mil) and increased from Dec. 2023 ($377.36 Mil) to Dec. 2024 ($382.25 Mil).


Penumbra Total Liabilities Historical Data

The historical data trend for Penumbra's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Penumbra Total Liabilities Chart

Penumbra Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 185.20 290.32 372.03 377.36 382.25

Penumbra Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 376.31 373.33 374.84 382.25 380.43

Penumbra Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Penumbra's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=158.345+(208.799+15.106
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=382

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=1533.181-1150.931
=382

Penumbra's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=158.63+(205.853+15.942
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=380

Total Liabilities=Total Assets (Q: Mar. 2025 )-Total Equity (Q: Mar. 2025 )
=1593.307-1212.882
=380

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Penumbra Total Liabilities Related Terms

Thank you for viewing the detailed overview of Penumbra's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Penumbra Business Description

Traded in Other Exchanges
Address
One Penumbra Place, Alameda, CA, USA, 94502
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
Executives
Adam Elsesser director, officer: Chairman, CEO and President 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Bridget O'rourke director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Thomas Wilder director 2 MUSICK, IRVINE CA 92618
Johanna Roberts officer: EVP, Gen. Counsel & Secretary PENUMBRA, INC., ONE PENUMBRA PLACE, ALAMEDA CA 94502
Harpreet Grewal director C/O VISTAPRINT USA, INCORPORATED, 100 HAYDEN AVE., LEXINGTON MA 02050
Arani Bose director, officer: Chief Innovator 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Lambert Shiu officer: Chief Accounting Officer ONE PENUMBRA PLACE, ALAMEDA CA 94502
Maggie Yuen officer: Chief Financial Officer ONE PENUMBRA PLACE, ALAMEDA CA 94502
Don W. Kassing director 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Surbhi Sarna director ONE PENUMBRA PLACE, ALAMEDA CA 94502
James Robert Pray officer: President, International 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Lynn Rothman officer: EVP and Chief Business Officer 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sridhar Kosaraju officer: CFO and Head of Strategy 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Janet Leeds director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Robert D. Evans officer: EVP, Gen. Counsel & Secretary ONE PENUMBRA PLACE, 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502